AI designed this drug, but humans took the patent

insilico medicine used generative ai to design a new drug for pulmonary fibrosis but named five humans as inventors on the patent, omitting the system's contribution. the discrepancy underscores current patent laws that only recognize humans as inventors, forcing companies to bypass acknowledging ai's role to secure intellectual property. as ai models become capable of generating drug candidates as easily as chatgpt writes text, the legal system faces increasing pressure to define authorship. this creates a growing tension between the reality of ai-aided research and the rigid requirements of intellectual property law.